FBXW7/hCDC4-β Methylation and Breast Cancer Prognosis
Author Information
Author(s): Akhoondi Shahab, Lindström Linda, Widschwendter Martin, Corcoran Martin, Bergh Jonas, Spruck Charles, Grandér Dan, Sangfelt Olle
Primary Institution: Karolinska Institute
Hypothesis
Is FBXW7/hCDC4 promoter methylation associated with prognosis in breast cancer?
Conclusion
FBXW7/hCDC4-β methylation is linked to a favorable prognosis in breast cancer despite its association with high-grade tumors.
Supporting Evidence
- 51% of primary breast tumors showed FBXW7/hCDC4-β promoter methylation.
- Methylation was associated with improved survival in patients with lymph node metastasis.
- FBXW7/hCDC4-β methylation was linked to lower expression of the gene.
- Statistical analysis showed significant differences in survival rates based on methylation status.
Takeaway
This study found that a specific change in the DNA of breast cancer cells can help doctors predict how well a patient will do, even if the cancer looks aggressive.
Methodology
The study analyzed FBXW7/hCDC4-β expression and promoter methylation in 161 breast cancer tumors using various statistical methods.
Limitations
The study was limited by the different treatment protocols used in the two cohorts.
Participant Demographics
Median age of participants was 64 years, with a range from 33 to 94.
Statistical Information
P-Value
P = 0.017
Confidence Interval
95% CI 0.23 to 1.23
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website